arrow
返回
S

Sungkyunkwan University School of Medicine

学者数48
论文数15
被引数0
关联论文 (14)
发表时间
PARP10 condensation inhibits viral replication via targeting NAD+ homeostasisPARP10凝聚通过靶向NAD+稳态抑制病毒复制
err2026-09-26
err0
errOAAI
errXiaoxin Chen; Qi Xu; Yi Liu; Zhenshuo Zhu; Ziqiu Wang; Yun Zhang; Ziru Li; Yunan Mao; Chenmiao Ai; Qi Chen; Le Tian; Zhiying Yao; Youngdae Gwon; Zhubing Shi; Peiguo Yang
err分享
err收藏
Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trialEvorpacept联合曲妥珠单抗、雷莫昔单抗和紫杉醇治疗HER2-positive胃癌: 一项随机2期试验
err2026-09-24
err0
errOAAI
errKohei Shitara; Zev Wainberg; Josep Tabernero; Eric Van Cutsem; Clélia Coutzac; Christelle De La Fouchardière; Jeeyun Lee; Sun Young Rha; Yoon-Koo Kang; Philip Fanning; Alison Forgie; Cherry Mao; Daniel Brickman; Jaume Pons; Athanasios C. Tsiatis; Sophia Randolph; Keun-Wook Lee
err分享
err收藏
Design and implementation of an EMR-embedded integrated cardio-cerebrovascular registry platform基于电子病历的集成心脑血管登记平台的设计与实现
err2026-09-23
err0
errOAAI
errDanbee Kang; Junwoo Seo; Hyung Jun Kim; Juwon Kim; David Hong; Yang-Jin Park; Ja Kyoung Yoon; Sang Yoon Lee; Sung-Ji Park; Siwon Oh; Tae Keun Jee; Wooseong Huh; Woo-Keun Seo; Sang-Chol Lee
err分享
err收藏
Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial曲妥珠单抗联合纳武利尤单抗与吉西他滨和顺铂作为HER2阳性不可切除胆道癌的一线疗法:一项1b/2期临床试验
err2026-09-22
err0
errOAAI
errChoong-kun Lee; Taek Chung; Il Hwan Kim; Hong Jae Chon; Jin Won Kim; Se Jun Park; Woo Kyun Bae; Junghun Kang; Changhoon Yoo; Dong-Hoe Koo; Sora Kang; Minsuk Kwon; Ju Won Kim; Beodeul Kang; Sejung Park; Woochan Hwang; Chang Ho Ahn; Chang Gon Kim; Hye Jin Choi
err分享
err收藏
Reply请提供需要翻译的标题或摘要内容。
err2026-09-22
err0
PREAI
errDong Kee Jang; Min Kyu Jung; Sang Hyub Lee
err分享
err收藏
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinibSAVANNAH研究的大众语言摘要:色瑞替尼联合奥希替尼用于EGFR突变型晚期非小细胞肺癌患者,这些患者的肿瘤在奥希替尼治疗后出现MET过表达和/或扩增,且肿瘤已进展或扩散。
err2026-07-16
err0
errOAAI
errFilippo de Marinis; Tae Min Kim; Laura Bonanno; Susanna Cheng; Sang-We Kim; Marcello Tiseo; Quincy Chu; Claudia Proto; Adrian Sacher; Yung-Hung Luo; Silvia Novello; Desiree Hao; Christina Baik; Lyudmila Bazhenova; Jong Seok Lee; Byoung Chul Cho; Jacques Cadranel; Tuan Bao Diep; Giulio Metro; Prasad Narayanan; Yasuto Yoneshima; Javier de Castro Carpeño; Clarissa Baldotto; James Chih-Hsin Yang; Lecia V. Sequist; Benjamin Levy; Ryan Hartmaier; Ike Igwegbe; Lynne Poole; Wanning Xu; Myung-Ju Ahn
err分享
err收藏